Understanding the mechanism by which tumor cells influence osteoclast differentiation is crucial for improving treatment of osteolytic metastasis. Here, we report broad microRNA (miRNA) expression changes in differentiating osteoclasts after exposure to tumor-conditioned media, in part through activation of NFkB signaling by soluble intracellular adhesion molecule (sICAM1) secreted from bone-metastatic cancer cells. Ectopic expression of multiple miRNAs downregulated during osteoclastogenesis suppresses osteoclast differentiation by targeting important osteoclast genes. Intravenous delivery of these miRNAs in vivo inhibits osteoclast activity and reduces osteolytic bone metastasis. Importantly, serum levels of sICAM1 and two osteoclast miRNAs, miR-16 and miR-378, which are elevated in osteoclast differentiation, correlate with bone metastasis burden. These findings establish miRNAs as potential therapeutic targets and clinical biomarkers of bone metastasis.
INTRODUCTION
Osteolytic bone metastasis is a frequent occurrence in late stage breast, lung, thyroid, bladder, and many other cancers, leading to pathological fractures, pain, and hypercalcemia (Weilbaecher et al., 2011) . The development of bone lesions depends upon the orchestrated interactions between tumor cells and functional cells within the bone, namely osteoblasts and osteoclasts (Ell and Kang, 2012; Weilbaecher et al., 2011) . The bone resorbing osteoclasts play an important role in physiological bone remod-eling (Boyle et al., 2003; Teitelbaum and Ross, 2003) , whereas aberrant osteoclast activity can lead to pathological conditions including Paget's disease and lytic bone metastasis (Weilbaecher et al., 2011) . Osteoclast differentiation is canonically dependent on two essential molecules, macrophage colonystimulating factor (M-CSF) and receptor activator of NF-kB ligand (RANKL) (Boyle et al., 2003; Teitelbaum and Ross, 2003) , although a number of RANKL independent pathways have been described (Hemingway et al., 2011) . Aberrant expression of these signaling molecules by bone-metastatic cancer
Significance
The activation and recruitment of osteoclasts is of vital importance for the development of osteolytic bone metastasis. Significant advances have been made in understanding tumor-stromal interactions that foster hyperactive osteoclast differentiation. However, the role of miRNAs in osteoclastogenesis during bone metastasis remains poorly understood. We show that tumor-conditioned media from multiple cancer types activates a consensus miRNA response signature in osteoclasts. This signature includes upregulated miRNAs that correlate with bone metastasis burden and show potential as clinical biomarkers. Importantly, functional studies reveal impaired osteoclast development and reduced bone metastasis burden after ectopic expression of downregulated miR-141 and miR-219. These findings establish miRNAs as essential regulators of osteoclastogenesis and potential therapeutic targets and biomarkers during bone metastasis. cells has been shown to recruit preosteoclasts to the site of osteolytic metastasis and induce their differentiation, leading to degradation of the bone and the subsequent release of bone matrix-embedded tumor-promoting growth factors such as TGFb (Ell and Kang, 2012; Korpal et al., 2009; Weilbaecher et al., 2011) . The role of osteoclasts in bone metastasis is further underscored by the efficacy of treatments targeting osteoclast differentiation and activity (Clé zardin, 2011) .
MicroRNAs (miRNAs) are a class of short ($22 nt) noncoding RNAs capable of repressing gene expression through complementary binding of the ''seed sequence'' of target mRNAs (Bartel, 2009 ). MiRNAs have been well recognized as playing vital roles in cellular processes such as differentiation and development (Kloosterman and Plasterk, 2006) , and numerous studies have linked aberrant miRNA expression to pathological conditions such as cancer (Croce, 2009) . Although a number of miRNAs have been identified as regulators of metastasis (Le et al., 2010) , the function of miRNAs in organ-specific metastasis to bone remains poorly understood. Furthermore, few studies to date investigate the role of stromal miRNAs as potential mediators and biomarkers of metastasis. Given the prominent role of osteoclasts in osteolytic bone metastasis, miRNAs that regulate osteoclastogenesis may play a key role in osteolytic bone metastasis. Recent findings have revealed a general necessity for miRNAs in osteoclastogenesis, as genetic or siRNA-mediated ablation of factors important for biogenesis of miRNAs, including Dicer1, Dgcr8, and Ago2, blocked osteoclast differentiation (Mizoguchi et al., 2010; Sugatani and Hruska, 2009 ). Additionally, ectopic expression of miR-155 (Mann et al., 2010; Mizoguchi et al., 2010; Zhang et al., 2012) or repression of miR-21 (Sugatani et al., 2011) inhibit osteoclast differentiation, whereas conflicting functions of miR-223 in osteoclastogenesis have also been reported Hruska, 2007, 2009) . Although these results indicate a crucial role for miRNAs in physiological osteoclast differentiation, a comprehensive understanding of miRNAs in pathological osteoclastogenesis is needed to evaluate their potential application in clinical management of bone metastasis. Here, we examine the miRNA expression changes during physiological and pathological osteoclastogenesis and evaluate the application of osteoclast miRNAs as possible therapeutic targets and biomarkers for metastatic disease.
RESULTS

Conditioned Media from Bone-Metastatic Cancer Cells Induces Osteoclast Differentiation
As previously shown (Sethi et al., 2011) , the murine preosteoclast cell lines RAW264.7 (Figures S1A and S1B available online) and MOCP-5 (data not shown) can be induced to differentiate into mature, multinucleated osteoclasts through the addition of 20-50 ng/ml RANKL. To examine the potential for tumorconditioned media (CM) to induce osteoclast differentiation, RAW264.7 or MOCP-5 preosteoclast cells were treated with CM from two pairs of cancer cell lines with differing bone metastasis capabilities: (1) the highly metastatic 4T1.2 mouse mammary tumor cell line and weakly metastatic 4T1 parental line (Lelekakis et al., 1999) , and (2) the highly metastatic TSU-Pr1-B2 human bladder cancer cell line and the weakly metastatic TSU-Pr1 parental line (Chaffer et al., 2005) . After 6 days of treat-ment with CM, TRAP staining revealed mature osteoclasts only in cells treated with CM from the highly bone metastatic 4T1.2 and TSU-Pr1-B2 ( Figures 1A and 1B ), although at significantly lower levels than treatment with 50 ng/ml RANKL (RANKL High ). Combined treatment of RAW264.7 cells with CM and a limited level of RANKL (20 ng/ml, RANKL Low ) significantly increased differentiation, approaching that seen by treatment with 50 ng/ml of RANKL ( Figures 1A-1C ). Treatment with CM induced similar differentiation in mouse bone marrow-derived primary preosteoclasts ( Figure S1C ) and MOCP5 cells (Figures S1D-S1F). Importantly, quantitative real-time reverse-transcriptase (RT)-PCR indicated that osteoclast genes were elevated in RAW264.7 cells upon treatment with RANKL and bone metastatic CM (Figures S1G and S1H). Taken together, these results indicate that bone-metastatic breast cancer cells are capable of secreting factors that induce differentiation and maturation of osteoclasts.
MiRNA Microarrays Reveal Differentially Regulated miRNAs
MiRNA microarray profiling was performed to compare miRNA expression changes in RAW264.7 cells treated for 7 days with CM from 4T1 versus 4T1.2 cells or CM from TSU-Pr1 versus TSU-Pr1-B2 cells, and with or without 50 ng/ml RANKL. A total of 334 mouse miRNAs were detected, revealing 42 upregulated and 45 downregulated miRNAs with a >2.2-fold change across treatment groups ( Figure 1D , left panel). As an initial step toward identifying miRNAs that may inhibit osteoclast differentiation, we focused on 22 unique miRNAs consistently downregulated across three sets of samples ( Figure 1D , right panel). Notably, there were significant correlations of miRNA expression changes between the treatment groups ( Figure 1E ), indicating conservation in the miRNA regulatory network during osteoclastogenesis in physiological and pathological conditions. Genes known to be important for osteoclast differentiation and function were examined for predicted miRNA binding sites based on TargetScan (Grimson et al., 2007) and PicTar (Krek et al., 2005) predictions (Table S1 ). Five miRNAs, were selected for further analysis based upon their significant downregulation, multiple predicted osteoclast targets, and sequence conservation between human and mouse. Quantitative real-time RT-PCR analysis confirmed that all five miRNAs examined decreased significantly after 6 days of RANKL treatment in RAW264.7, primary bone marrow-derived precursors ( Figure 1F ) and MOCP-5 cells (data not shown). Importantly, these miRNA changes were also observed during the differentiation of primary human osteoclasts (Figures S1I-S1K).
Ectopic Expression of miRNAs Inhibits Osteoclast Differentiation
To examine the functional role of the downregulated miRNAs in osteoclastogenesis, we ectopically expressed the miRNAs in preosteoclast cells prior to RANKL-induced osteoclast differentiation. Overexpression of all five miRNAs resulted in a significant decrease in osteoclast differentiation in both RAW264.7 cells ( Figure 2A ) and primary preosteoclasts (Figure S2A) . We observed no change in cell growth or apoptosis after any of the miRNA treatments (data not shown). The defect in osteoclastogenesis was confirmed by quantitative real-time RT-PCR analysis that found repression of multiple osteoclast marker genes after ectopic miRNA expression ( Figure S2B ). In vitro bone resorption assay was then used to measure the effect of ectopic miRNA expression on osteoclast activity. Interestingly, although miR-33a caused only a small decrease in bone resorption, the remaining four miRNAs dramatically limited osteoclast activity ( Figure 2B ).
Because these miRNAs might inhibit osteoclast differentiation or function by targeting different mRNAs, we further examined the repression of osteoclast differentiation using combinations of inhibitory miRNAs. Given that transient transfection with 10 pM of miRNA precursors was sufficient to inhibit up to $90% of osteoclast differentiation, we treated RAW264.7 cells with a combination of miRNAs at a reduced concentration of 1 pM total precursors. Combined ectopic expression of miR-141, miR-190, and miR-219 revealed a significant additive effect on osteoclast maturation ( Figure 2C ) and bone resorption (Figures 2D and S2C) that is equivalent to the treatment with 20 nM zoledronic acid ( Figures 2D and S2C ). Importantly, ectopic expression of the miRNAs combined with zoledronic acid revealed an additive effect, leading to almost complete ablation of osteoclast activity ( Figures 2D and S2C) . These results reveal a necessity for repression of multiple miRNAs during osteoclast differentiation, with ectopic expression of miR-133a, miR-141, and miR-219 strongly inhibiting osteoclast maturation 4T1 TSU RANKL 4T1 TSU RANKL See also Figure S1 and Table S1 . and activity in all models tested and partial inhibition seen after ectopic expression of miR-33a and miR-190.
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To confirm that miRNA-mediated inhibition of osteoclast differentiation is not specific to the RAW264.7 model, we examined the effect of ectopic miRNA expression in additional models. MOCP5 cells transfected with pre-miRNAs revealed a similar pattern of inhibition ( Figures S2D and S2E) . A previous study revealed greatly enhanced osteoclast differentiation after activation of the Notch pathway by tumor-derived Jagged1 (Sethi et al., 2011) . To examine the effect of miRNAs on Jagged1enhanced osteoclast differentiation, RAW264.7 cells were plated on Jagged1-coated plates, followed by treatment with 50 ng/ml RANKL. Ectopic miRNA expression significantly inhibited Jagged1-dependent enhancement of osteoclast differentiation ( Figures S2F-S2H ). Taken together, these results illustrate the broad capacity for ectopic expression of these miRNAs to inhibit osteoclast differentiation.
Identification of miRNA Targets Involved in Osteoclast Differentiation and Function
We sought to examine direct miRNA targeting of mRNAs related to osteoclastogenesis using luciferase reporters containing the 3 0 UTR of prospective target mRNAs (Table S2 ). Reporter constructs were cotransfected with pre-miRs, as well as a Renilla luciferase plasmid for normalization. Reporter assays revealed a number of direct targets for the candidate miRNAs. MiR-133a, miR-141, and miR-219 were all found to repress expression of Mitf, and specific targeting of Mitf by these miRNAs was confirmed by site-directed mutagenesis of the predicted miRNA binding sites ( Figures 3A-SC) . Interestingly, miR-141 was found to contain two active binding sites in the Mitf 3 0 UTR, reducing expression by $50% (Figure 3B ), whereas a single site in miR-219 was able to repress Mitf expression by $20% ( Figure 3C ). In addition, miR-133a was found to repress Mmp14, miR-141 repressed Calcr, miR-219 repressed Traf6, and miR-190 was able to repress Calcr ( Figures 3A-3D ). These miRNA targets represent important factors involved in osteoclast differentiation and function, with Mitf functioning as an essential transcription factor, Calcr and Traf6 serving as important signal transducers, and Mmp14 functioning as a secreted matrix metalloproteinase during osteoclastogenesis ( Figure 3E ). To better examine the capacity of the miRNAs to inhibit osteoclast differentiation, osteoclast markers were examined in RAW264.7 cells transfected with the miRNA of interest, followed by RANKL Table S2. treatment. Western blot analysis of Pu.1, Nfatc1, and Ctsk revealed that miR-133a, miR-141, and miR-219 seem to be inhibiting early osteoclast differentiation, with minimal expression of Nfatc1, which plays a role in early osteoclast commitment, or the mature osteoclast marker Ctsk (Teitelbaum and Ross, 2003 ) ( Figure 3F ). These results are in agreement with their targeting of Mitf or Traf6, either of which is predicted to inhibit the earliest stages of osteoclast commitment. In comparison, miR-190 transfected cells expressed Pu.1 and Nfatc1, but not Ctsk, indicating that miR-190 might be inhibiting osteoclast differentiation after commitment to an osteoclast fate. miR-33a-transfected cells retained expression of all three osteoclast genes, consistent with its relatively weak effect on inhibiting osteoclastogenesis ( Figure 3F ). Taken together, these results indicate that the miRNAs are inhibiting osteoclast differentiation through the functional targeting of essential osteoclast genes functioning at different stages of osteoclast differentiation.
Systemic miRNA Treatment Inhibits Osteoclasts In Vivo
To evaluate the capacity for these miRNAs to inhibit mouse osteoclast function in vivo, we injected 10 mg of pre-miRNA into the lateral tail-vein of Balb/c mice weekly for 4 weeks. Mice were examined weekly by X-ray radiography, revealing increased bone density in the hind limbs, particularly in the distal femur and proximal tibia (data not shown). Examination by microCT revealed increased trabecular bone in both femur and tibia ( Figure 4A ). Further quantitative analyses confirmed a significant increase in bone volume ( Figure 4B ) and trabecular thickness ( Figure 4C ), whereas no significant differences in cortical bone thickness was found ( Figures 4A and 4D ). Histological TRAP staining of decalcified bone sections revealed a significant decrease in the number of osteoclasts relative to bone surface area in mice treated with miR-141 and miR-219 (Figures 4A and 4E) and Von Kossa staining revealed the increase of calcified tissues ( Figure 4A ), confirming the significant expansion in trabecular bone that was seen in the microcomputed tomography (microCT) analysis. Osteocalcin immunohistochemical staining revealed no significant difference in osteoblast number (Figures 4A and 4F) , which is consistent with a previous report that inhibition of miRNA biogenesis does not affect osteoblast differentiation (Mizoguchi et al., 2010) . Although these results indicated osteoclasts as a major bone cell type affected by systemic delivery of these miRNAs, it is important to note that the differentiation or activity of additional bone stromal cells might also be impacted.
MiR-141 and miR-219 Inhibit Experimental Bone Metastasis
Given the ability of multiple miRNAs to inhibit osteoclast differentiation in vitro and in vivo, we next examined the capacity of these miRNAs to inhibit breast cancer bone metastasis in a mouse model. We first examined the potential of CM from multiple SCP cell lines, clonal derivatives of the human MDA-MB-231 breast cancer line (Kang et al., 2003) with different bone metastatic capabilities, to regulate osteoclast differentiation. Similar to our previous results (Blanco et al., 2012) , CM from highly bone metastatic SCP cell lines (SCP2, SCP28, and SCP46), but not from weakly metastatic lines (SCP4, SCP6, and parental MDA-MB-231), stimulated osteoclast differentiation in RAW264.7 cells ( Figures S3A and S3B ), increased the expression of osteoclast marker genes ( Figure S3C ), and induced miRNA expression changes consistent with our previous findings ( Figure S3D ). After further validating the ability of highly metastatic SCP28 to induce osteoclastogenesis in MOCP5 cells ( Figures S3E-S3G ), we used SCP28 for analyzing the effect of miRNAs on bone metastasis development in mice.
Nude mice were systemically treated with control or experimental pre-miRNAs immediately before, and once per week subsequently, after inoculation with SCP28 cells via intracardiac injection. Metastatic progression was monitored by weekly bioluminescence imaging (BLI) using a firefly luciferase reporter stably expressed in the cell line. Whereas treatment with miR-133a and miR-190 had no effect on metastatic progression by BLI, there was a significant decrease in hind-limb tumor burden after treatment with either miR-141 (p = 0.024) or miR-219 (p = 0.015) ( Figures 5A and 5B) . Quantitative real-time RT-PCR analysis of serum samples from mice inoculated with the pre-miRNAs revealed a substantial decrease in miR-190 and miR-133a within 6 hr of injection, with nearly full clearance within 24 hr ( Figure 5C ). In contrast, miR-141 and miR-219 took substantially longer to clear from the serum, maintaining $20% of the normalized expression at 24 hr. X-ray imaging revealed decreased bone lesions in miR-141-and miR-219-treated mice, whereas miR-190, miR-133a, and control pre-miRNA-injected mice exhibited significant bone degradation (Figures 5A and 5D) . Histological analysis revealed a decrease in osteolysis by hematoxylin and eosin (H&E) staining and a decrease in TRAP + osteoclast recruitment at the tumor-bone interface. Consistent with the results in miRNA-treated healthy mice (Figure 4) , miR-190-, miR-141-, and miR-219-treated mice showed a significant decrease in TRAP + osteoclast number ( Figure 5E ), whereas there was no noticeable change in osteoblast number from any of the treatments ( Figures 5A and 5F ). To rule out the potential influence of the miRNAs on the growth or survival of the SCP28 cells, we treated the cells with miRNAs in culture and found no significant difference in proliferation (data not shown). Taken together, these results reveal a significant decrease in metastatic burden after systemic treatment with miR-141 or miR-219, likely due to decreased osteoclast activity.
We further compared the therapeutic effect of miRNAs with treatment of 100 mg/kg zoledronic acid (Zometa) ( Figures S3H  and S3I ). As expected, mice treated with Zometa experienced a significant decrease in tumor burden, with an overall trend of better response than individual miR-141 or miR-219 treatment, although the difference did not reach statistical significance. These results indicate that systemic treatment with miR-141 and miR-219 inhibits bone metastasis burden to a similar extent as current therapeutics.
Serum miRNA Levels Correlate with Bone Metastasis
To further evaluate the function of miRNAs that change during osteoclast differentiation we next examined a subset of four miRNAs with significant upregulation during osteoclastogenesis (miR-16, miR-211, miR-378, and Let-7a, Figure 1D ). Interestingly, we did not observe significant differences after ectopic expression or repression of any of the candidate miRNAs tested, although this result did not rule out the functional importance of additional candidates that we have not tested so far. As miRNAs are often released from cells into circulation, miRNAs with increased expression during osteoclastogenesis may potentially serve as biomarkers for osteolytic bone metastasis. To evaluate the possibility of using osteoclast miRNAs as biomarkers, we examined the expression of miRNAs upregulated during osteoclastogenesis ( Figure 1D ) in serum samples of mice with different bone metastasis burdens. Serum samples were collected at 0, 7, and 35 days from nude mice after intracardiac injection of highly metastatic SCP2 cells and miRNA expression was analyzed by quantitative real-time RT-PCR. Examination of multiple miRNAs with the most dramatic increase during differentiation revealed consistently elevated expression of miR-378 and miR-16 at 35 days postinjection ( Figure 6A) . Similarly, only miR-378 and miR-16 were elevated when we compared mice with low or high bone metastatic tumor burden after inoculation with weakly metastatic TSU-Pr1 or highly metastatic TSU-Pr1-B2 cell lines, respectively ( Figure 6B ). Based on these findings, we examined the expression of miR-378 and miR-16 in matched primary (Primary) or bone-metastatic (BM) tumor samples from 12 breast cancer patients. Both miR-16 and miR-378 have elevated expression in bone metastases, reflecting the presence of osteoclasts ( Figure 6C ). Next, we analyzed the expression of these two miRNAs in serum samples of healthy female donors (HD) or breast cancer patients with bone metastasis (BM) and again observed significantly increased level of both miRNAs in patients with bone metastasis ( Figure 6D ). Taken together, these results indicated the potential for using these miRNAs as biomarkers for bone metastasis progression.
Soluble ICAM1 from Metastatic Cells Enhances Osteoclast Differentiation
Because tumor CM-induced osteoclastogenesis produced similar miRNA changes to RANKL-induced physiological osteoclast differentiation, we decided to identify soluble factor(s) in CM that promote osteoclast activation. First, we investigated whether RANKL present in CM is accountable for such activities.
ELISA quantification of RANKL levels in CM samples revealed very low levels (4-6 ng/ml) of RANKL even in highly metastatic MDA-MB-231, 4T1, or TSU sublines, although these sublines produced significantly higher levels of RANKL than their weakly metastatic isogenic counterparts ( Figure S4A ). These levels of RANKL are insufficient to induce osteoclast differentiation (see Figures S1A and S1B ). Furthermore, osteoclast differentiation induced by 30 ng/ml RANKL is inhibited by more than 80% after treatment with 200 ng/ml of OPG, a decoy receptor and inhibitor of RANKL. In contrast, such treatment resulted in only $50% inhibition of CM induced osteoclast differentiation ( Figures 7A and  S4B) . These results indicated that additional factor(s), other than RANKL, in the tumor CM play an important role in enhancing osteoclastogenesis. A number of RANKL-independent osteoclast differentiation factors have been previously described, such as IL-6, MIF-1a, PTHrP, TNFa, GM-CSF, and IGF (Weilbaecher et al., 2011) . To examine whether any of these or other cytokines were secreted by the metastatic cells to induce osteoclastogenesis, we evaluated cytokine expression in CM from the three series of cell lines with differential bone metastatic abilities (Figure 7B) . Interestingly, among the cytokines analyzed, only soluble ICAM1 (sICAM1), the cleaved extracellular domain of ICAM1, was consistently overexpressed in the highly metastatic cell lines. Cell surface ICAM1 has been previously implicated in osteoclast differentiation, and antibodies against ICAM1 reduce osteoclast maturation (Harada et al., 1998; Kurachi et al., 1993) . However, the functional role and mechanism of tumor-derived sICAM1 in osteoclastogenesis is unknown. Treatment of RAW264.7 cells with 50 ng/ml sICAM1 and 50 ng/ml RANKL together prompted osteoclast differentiation within 2 days, whereas treatment with RANKL alone required $4 days for the first mature osteoclasts to differentiate ( Figure 7C ). Analysis of osteoclast marker genes confirmed that sICAM1 treatment, together with 50 ng/ml RANKL, reduced the time necessary for osteoclast differentiation compared to RANKL treatment alone, although there was no difference in endpoint expression levels for any of the mRNAs ( Figure S4C ). Although sICAM1 alone was not sufficient to induce differentiation, it exhibited an additive effect on differentiation when combined with limiting concentrations of RANKL (10 ng/ml RANKL, Figure 7D ) and a significant inhibition in the expression of miRNAs downregulated during osteoclastogenesis, which was magnified after cotreatment with RANKL ( Figure 7E ). Because the ELISA results from CM samples revealed very low RANKL concentrations that are insufficient to support oste-oclast maturation, and treatment with sICAM1 and RANKL revealed an additive effect, we hypothesized that CM-induced differentiation was due to the combined effect of both secreted factors. To test this, RAW264.7 cells were treated with 4 ng/ml RANKL (equivalent to the level in tumor CM) and increasing concentrations of sICAM1. Although low levels of sICAM1 had no effect on RAW264.7 cells in the presence of 4 ng/ml RANKL, we observed high levels of TRAP + osteoclasts after treatment with 50 ng/ml sICAM1, approaching that of CM treatments (Figures 7F and S4D ). Furthermore, when RAW264.7 cells were cultured with a function blocking monoclonal antibody (mAb) against ICAM1, they exhibited a dose-dependent decrease in osteoclast differentiation ( Figures 7G and S4E) induced by SCP28 CM, whereas RANKL-induced osteoclastogenesis was unaffected. Additionally, treating SCP28 CM with sICAM1 mAb resulted in an additive inhibitory effect when combined with OPG ( Figure S4F ), and ICAM1 mAb was able to inhibit the bone resorbing activity of CM-treated RAW264.7 cells (Figure S4G) . Finally, RAW264.7 cells treated with sICAM1 showed increased migration in a dose-dependent manner, which was once again inhibited by the ICAM1 mAb ( Figure S4H ). Taken together, these results support a functional role for sICAM1 as a crucial component of tumor CM in stimulating osteoclastogenesis.
Previous studies have identified aLb2 and aMb2 integrins as receptors of sICAM1 (Carlos and Harlan, 1994) . Indeed, a function-blocking antibody against the b2 subunit inhibited SCP28 CM-induced, but not RANKL-induced, differentiation ( Figures  8A and S4I ). Analysis of RAW264.7 cells revealed strong expression of aM and b2 subunits on the cell surface and lower expression of aL ( Figure 8B ). Signaling through b2 integrins has been previously shown to activate the NFkB pathway in neutrophils under stimulation by GM-CSF or IL-6 (Kettritz et al., 2004) , although it is not known if sICAM1 can similarly activate NFkB. We examined activation of the pathway by monitoring the activation of an NFkB luciferase reporter ( Figure 8C ), degradation of IkBa ( Figure 8D ), or phosphorylation of p65 ( Figure S5A ) in RAW264.7 cells treated with TNFa, RANKL, or sICAM1 over time and observed similar responses in these three treatment conditions. SCP28 CM treatment also showed a decrease in IkBa, which was inhibited by the addition of an antibody against the b2 integrin or OPG ( Figure 8E) . Similarly, the b2 integrin antibody inhibited sICAM1-induced activation of NFkB ( Figure S5B ) but had no effect on NFkB signaling in RANKL-treated cells. Interestingly, although sICAM1-induced miRNA changes were abrogated after RAW264.7 cells were treated with the IKK inhibitor PS1145 ( Figure 8F ), miRNA transfection did not affect NFkB activation induced by TNFa, RANKL, or sICAM1 ( Figures S5C  and S5D ), suggesting that these miRNAs act downstream of NFkB activation to influence osteoclastogenesis. Together, these results implicate sICAM1 as a bone metastatic cellsecreted factor that functions through b2 integrin and NFkB signaling to enhance osteoclast differentiation in the presence of low levels of RANKL.
Correlation of Serum sICAM1 and miRNA Expression in Patients with Bone Metastasis
To further investigate the clinical significance of sICAM1 as a tumor-derived factor in inducing osteoclastogenesis and (legend continued on next page)
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Osteoclast miRNAs in Bone Metastasis associated miRNA changes during bone metastasis, we analyzed the expression levels of sICAM1 in serum samples collected from HD, disease-free breast cancer patients (DFP) showing no occurrence of bone metastasis (samples taken immediately following resection of the primary tumor), or breast cancer patients with BM. Patients with bone metastases exhibited significantly increased serum sICAM1 level compared to healthy donors or disease-free patients ( Figure 8G ). Importantly, a strong correlation was seen between serum expression of sICAM1 and miR-16 or miR-378 ( Figure 8H ) in bone metastasis patients, whereas little correlation was seen in samples from healthy donors.
To further investigate the diagnostic potential of miR-16 and miR-378 as secreted biomarkers for osteolytic bone metastasis, we compared the serum expression of the miRNAs against N-ter- minal telopeptide (NTX), a standard marker of bone turnover. The sensitivity and specificity of using serum levels of miR-16, miR-378, sICAM1 and NTX, alone or in combination, for detecting bone metastasis were determined (Figures S5E and S5F) . The diagnostic values of miR-378 and sICAM1 were lower than that of either miR-16 or NTX as individual variables, and combining sICAM1 with NTX did not significantly increase the value. In contrast, miR-16 revealed increased specificity over NTX, while maintaining a similar sensitivity. Importantly, the combination of miR-16 with NTX produced increased sensitivity, with only a slight reduction in specificity ( Figure S5F) . These findings underscored the clinical significance of elevated sICAM1 and miR-16/-378 expression in the serum of bone metastasis and suggest their potential use as biomarkers for diagnosis of bone metastasis or predictive marker for anti-ICAM1 therapeutics.
DISCUSSION
The present study provides experimental and clinical evidence to support the role of miRNAs in osteoclast activation
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Osteoclast miRNAs in Bone Metastasis during breast cancer bone metastasis. Genetic ablation of Dicer in the osteoclast lineage has clearly established the importance of miRNAs in physiological osteoclast development (Mizoguchi et al., 2010; Sugatani and Hruska, 2009 ). However, little is known about miRNA regulation during tumorinduced osteoclastogenesis. In this study, we revealed consistent up-and downregulated miRNAs during osteoclast differentiation in both physiological and pathological conditions. We demonstrated inhibition of osteoclast differentiation and osteolytic bone metastasis after ectopic expression of several miRNAs downregulated during osteoclastogenesis. We further identified sICAM1 as an important tumor-secreted factor that enhances osteoclast differentiation and influences osteoclast miRNA expression via the NFkB pathway. Importantly, serum levels of both sICAM1 and miRNAs are indicators of bone metastasis burden in breast cancer patients. These results suggest multiple avenues for clinical translation of the findings.
A previous microarray-based analysis of miRNA expression changes in mouse primary osteoclasts was conducted 24 hr after M-CSF/RANKL treatment and revealed altered expression of dozens of miRNAs (Sugatani et al., 2011) . In our current study, we focus on miRNA changes induced by both RANKL and tumor-conditioned media, and samples were collected after 7 days of treatment with RANKL or CM, after we observed full osteoclast differentiation. Such analysis is likely to reveal not only miRNAs involved in regulating osteoclast differentiation, but also those that influence the function of mature osteoclasts. Notably, although our miRNA microarray analysis revealed similar trends of expression changed in miRNAs reported in the previous study (Sugatani et al., 2011) (Figure S5G ), a distinct set of most differentially expressed miRNAs were identified in (C) Quantification of TRAP + osteoclasts from RAW264.7 cells treated with 50 ng/ml RANKL ± 50 ng/ml sICAM1 for indicated length of time. ***p < 0.001. (D) Quantification of TRAP + osteoclasts from RAW264.7 cells treated with 10 ng/ml RANKL, 50 ng/ml sICAM1, or both for 6 days. *p < 0.05. (E) Quantitative real-time RT-PCR analysis of selected miRNAs in RAW264.7 cells after indicated length of treatment with 10 ng/ml RANKL or/and 50 ng/ml sICAM1. *p < 0.05 by ANOVA for all miRNAs.
(F) Quantification of osteoclasts/field and nuclei/osteoclast in RAW264.7 cells treated with 4 ng/ml RANKL plus indicated concentration of sICAM1 for 6 days. **p < 0.01, ***p < 0.001. (G) Quantification of TRAP + osteoclasts from RAW264.7 cells treated with 30 ng/ml RANKL or SCP28-conditioned media followed by treatment with indicated concentration of ICAM1 antibody (in mg/ml). *p < 0.05, **p < 0.01. Data in the figure represent average ± SEM; p values were based on Student's t test unless otherwise indicated. See also Figure S4 .
Osteoclast miRNAs in Bone Metastasis our current study. It is possible that the differences across the two studies can be explained by the differences in cell lines used, treatment conditions, and time points analyzed. Importantly, we used three different human and mouse cancer cell lines from two different tumor types in the CM treatment experiments. Despite the fact that these three distinctively different tumor cells all secrete a subminimal amount of RANKL into their CM, miRNA expression changes stimulated by their CM showed high levels of consistency with RANKL-induced osteoclastogenesis. Moreover, ectopic overexpression of downregulated miRNAs inhibited osteoclastogenesis induced by multiple condi-tions, including RANKL, tumor CM, and Jagged1, in multiple osteoclast cell lines or primary preosteoclasts. These findings support a highly conserved miRNA regulatory network that controls osteoclast differentiation in both pathological and physiological conditions. Our investigation into the functional target genes of osteoclast-inhibiting miRNAs revealed direct targeting of a number of known osteoclast genes, including Mitf, Calcr, Traf6, and Mmp14, by these miRNAs. MITF is a basic-helix-loop-helixzipper transcription factor (Hodgkinson et al., 1993) that is crucial for osteoclast development (Hershey and Fisher, 2004; Sharma 
Osteoclast miRNAs in Bone Metastasis Weilbaecher et al., 2001) . Traf6 encodes a member of the tumor necrosis factor receptor (TNFR)-associated factor family of cytokine receptor adaptor proteins that play an essential role in signaling transduction of the RANKL pathway (Lomaga et al., 1999) . Calcitonin receptor (CALCR) is a well characterized cell-surface receptor capable of influencing osteoclast-mediated bone resorption in vitro and in vivo (Davey et al., 2008) .
Mmp14 knockout mice feature severe skeletal defects, including osteopenia and skeletal dysplasia (Holmbeck et al., 1999) . Interestingly, additional studies have implicated Mmp14 in osteoclast fusion during maturation, and Mmp14 null osteoclasts had decreased activity in vitro (Gonzalo et al., 2010) . Therefore, decreased expression of Mitf, Traf6, Calcr, or Mmp14 is likely to constitute a miRNA target gene network responsible for the defect we see in osteoclast differentiation after ectopic expression of these miRNAs. Our analysis of stage-specific markers of osteoclast differentiation revealed that miR-133a, miR-141, and miR-219 seem to be inhibiting early osteoclastogenesis, whereas miR-190 might inhibit osteoclast differentiation or function after commitment to an osteoclast fate. CM from highly bone metastatic cells was able to induce osteoclast differentiation and miRNA expression changes despite the presence of very low levels of RANKL, which is insufficient to induce osteoclastogenesis. Importantly, we identified sICAM1 as a tumor-derived factor in the CM that enhances osteoclast activation at the minimal concentration of RANKL. ICAM1 has been previously observed to increase in expression level during osteoclast differentiation, whereas ablation of ICAM1 inhibited osteoclast differentiation from peripheral blood mononuclear cells (Nakano et al., 2004) . However, it was previously unknown how tumor-derived sICAM1 influences osteoclast differentiation. Our discovery that sICAM1 is capable of increasing RANKLinduced osteoclast differentiation reveals an additional mechanism for osteoclast regulation from bone metastatic cells and suggests a potential target for therapeutic intervention. Various tumor-derived factors have been previously shown to induce osteoclast differentiation, including cell surface ligand Jagged1 and secreted factors RANKL, GM-CSF, MIP-1a, PTHrP, IL-8, and IL-6 (Ell and Kang, 2012; Weilbaecher et al., 2011) . Our findings indicate a similar role for tumor-secreted ICAM1, which is insufficient for independently inducing osteoclastogenesis but capable of enhancing differentiation in the presence of low, but physiological, levels of RANKL. We found that sICAM1 binding to its cognate receptor b2 integrins activates NFkB signaling, which is essential for canonical, RANK-mediated osteoclast differentiation (Boyle et al., 2003; Teitelbaum and Ross, 2003) , potentially explaining the mechanism by which sICAM1 enhances osteoclast differentiation. Although it is not known how b2 integrins activate the NFkB pathway, it has been proposed that they provide a costimulatory effect on NFkB signaling in neutrophils treated with GM-CSF or IL-8 (Kettritz et al., 2004) . Furthermore, b2 integrin clustering can activate NFkB (Kim et al., 2004) . Importantly, sICAM1-induced alterations in miRNA expression appear to occur downstream of NFkB, as inhibiting the pathway prevented miRNA changes, whereas none of the miRNAs examined in this study altered NFkB signaling. Additionally, sICAM1 increases the migration of preosteoclast cells, which may indicate a role for bone-metastasis derived sICAM1 in the recruitment of osteoclasts to the developing bone lesion. This hypothesis is in line with results from a previous study that identified soluble VCAM1 as an important bone metastasis factor in the recruitment of osteoclasts to the osteolytic lesion through the binding of a4b1 integrins on preosteoclast cells (Lu et al., 2011) . Notably, VCAM1 and ICAM1 are both endothelial adhesion molecules of the Ig gene superfamily that bind leukocyte integrins. It is therefore not surprising that they have conserved functions in enhancing osteoclastogenesis in bone metastasis.
Our findings reveal several avenues for potential translational applications in the clinical management of bone metastasis. Intravenous injection of pre-miR-133a, pre-miR-141, pre-miR-190, or pre-miR-219 significantly reduced osteoclast activity in vivo. These effects were seen most clearly in the trabecular region of the femur and tibia, whereas no significant difference was seen in cortical bone thickness. This finding is similar to the observation in animals treated with bisphosphonates (Quattrocchi et al., 2012) , possibly because of the higher rates of turnover in the trabecular bone. Consistently, treatment of mice with the pre-miR-141 and pre-miR-219 was capable of inhibiting osteolytic bone metastasis. It is curious that miR-133a and miR-190 had no measurable effect on bone metastasis, despite a substantial influence on normal bone remodeling. It seems unlikely that this is due to a tumor-intrinsic mechanism, because in vitro studies showed no effect on SCP28 growth or survival after miRNA treatment. Instead, is possible that this is explained by the measured differences in stability of the miRNAs in circulation, as inhibition of bone metastasis may require greater levels of miRNAs to reach the bone than inhibition of normal bone remodeling.
In our studies, systemic injection of unconjugated miRNAs was sufficient to induce broad changes in bone remodeling and appeared to be well-tolerated by the mice. Although our data from in vitro and in vivo experiments illustrate miRNAmediated inhibition of osteoclasts, it is possible that these miRNAs might also target additional cells in vivo. Therefore, additional further analyses of other potential cellular and molecular targets of these miRNAs during long-term treatment in vivo should be conducted when developing potential miRNA-based therapeutic applications. It is possible that improved delivery methods might enhance the pharmacokinetics and efficacy of the miRNAs on bone metastasis and potentially reveal an effect from miR-133a and miR-190. The therapeutic effects of miR-141 and miR-219 mimic those seen in mice after treatment with Zometa. In addition, we noted an additive effect from combined treatment with miR-141/-190/-219 and Zometa on bone resorption in vitro. Thus, it is possible that combinatorial treatments including miRNAs and currently approved osteoclast-targeting agents such as biosphosphonates and denosumab (RANKL antibody) might provide enhanced clinical efficacy. Furthermore, the functional role of tumor-derived sICAM1 in pathological osteoclast differentiation suggests the potential for using ICAM1 blocking antibodies for targeted therapeutics. Therefore, osteoclast miRNAs and sICAM1 represent potential targets in the treatment of aberrant osteoclast activity, namely bone degenerative diseases such as osteolytic bone metastasis, osteoporosis, and Paget's disease. Finally, our discovery that miR-16 and miR-378 levels increase in bone lesions and serum samples of bone metastasis patients presents the potential for their use as metastasis biomarkers. In particular, combined miR-16 and NTX as biomarkers increased the sensitivity of bone metastasis diagnosis, although the potential clinical application of this combination still awaits further large scale prospective analysis.
EXPERIMENTAL PROCEDURES
Tumor Xenografts and Bioluminescence Analysis All procedures involving mice and experimental protocols were approved by Institutional Animal Care and Use Committee (IACUC) of Princeton University. For bone metastasis studies, 1 3 10 5 tumor cells were injected into the left cardiac ventricle of anesthetized female athymic Ncr-nu/nu. MiRNA precursors (10 mg/mouse in 100 ml PBS, Applied Biosystems) and Zometa (100 mg/kg) were injected intravenously. Development of metastases was monitored by measuring photon flux of BLI signals in the hindlimbs of mice after retro-orbital injection of 75 mg/kg D-Luciferin and image acquisition using the Xenogen IVIS 200 Imaging System. Data were normalized to the signal on day 0. X-ray examination was performed as previously described (Kang et al., 2003) .
Analysis of Primary Tumors and Bone Metastases
Women with resected breast cancer were selected from patients followed from 1995 to 2010 in IRCCS IRST, Meldola, Italy. Tumor specimens were de-identified and were considered exempt samples in accordance with the institutional review board of the Local Ethic Committee, Forlì, Italy. Tumor specimens were fixed in formalin and embedded in paraffin. Tissues collected were 13 matched primary breast tumors and 13 bone metastatic tissues. Total RNA was collected from 20 mm thick sections from formalin-fixed paraffin embedded (FFPE) tissue blocks using the FFPE RNA/DNA Purification kit (Norgen) according to the manufacturer's instructions.
Serum Case Series and Sample Collection
Breast cancer patients with no evidence of disease for at least 5 years (16 patients) and patients at first diagnosis of bone metastases (38 patients, radiologically confirmed) were recruited by the Osteoncology and Rare Tumors Center of IRCCS IRST (Meldola, Italy) from January 2007 to December 2009. A group of 41 healthy donors was also enrolled in the study. Informed consent was obtained from all subjects in accordance with the protocol approved by the institutional review board of the Local Ethic Committee, Forlì, Italy. A 5 ml venous blood sample from donors and patients was collected in tubes without anticoagulant and centrifuged at 2,500 rpm for 15 min at room temperature then stored at À80 C until processing. Total RNA from 400 ml of serum was extracted using the miRVana miRNA isolation kit (Ambion) according to the manufacturer's instructions.
Statistical Analysis
Results are presented as average ± SD or as average ± SEM, as indicated in figure legends. BLI signals were analyzed by nonparametric Mann-Whitney test. For serum markers analysis, in the absence of internationally available cut off values for markers, the cut off values maximally discriminating between patients with no evidence of disease and BM patients were identified using receiver operating characteristic (ROC) curve analysis. Sensitivity and specificity were calculated, and their statistical significance was analyzed by chi-square test comparing BM patients versus patients with no evidence of disease or versus healthy donors. The correlation between serum levels of the markers was assessed with the Spearman rank test. The diagnostic relevance of the combinations NTX-mir16 and NTX-sICAM1 considered as continuous variables (subjected to natural logarithmic transformation) was analyzed by the logistic regression model. The linear predictor or logit resulting from the model was used as a diagnostic test on which the ROC curve was calculated (Flamini et al., 2006) . Statistical analysis was done using SPSS software. All other comparisons were analyzed by unpaired, two-sided, independent Student's t test without equal variance assumption, unless otherwise described in figure legends.
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The raw and normalized microarray data have been deposited in the Gene Expression Omnibus (GEO) database under accession number GSE44936.
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